Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) a Bioelectronic healing approach

Transcutaneous auricular vagus nerve stimulation, commonly abbreviated as taVNS, is a non invasive neuromodulation technique that delivers low level electrical stimulation to the auricular branch of the vagus nerve located in the outer ear. This approach represents a significant advancement in the field of bioelectronic medicine, offering a safe and accessible alternative to surgically implanted vagus nerve stimulation devices.

The vagus nerve is the longest and most complex of the cranial nerves, serving as a primary highway of communication between the brain and the body's internal organs. It is a key component of the parasympathetic nervous system, often described as the rest and digest system, and plays a critical role in regulating heart rate, digestion, immune function, inflammation, and mood. The discovery that a branch of this nerve innervates the external ear, specifically the cymba conchae and tragus, provided the anatomical basis for non invasive stimulation.

Unlike its surgically implanted counterpart, which requires an invasive procedure and carries risks of infection, vocal cord paralysis, and other complications, taVNS is applied externally using small electrodes placed on the skin of the ear. This makes it a far more practical and appealing option for both clinical and home based use. Since its development, taVNS has been investigated for a wide array of conditions, including epilepsy, depression, chronic pain, stroke rehabilitation, Parkinson's disease, tinnitus, and inflammatory disorders. The accumulating body of research, including high quality randomized controlled trials published in recent years, supports its therapeutic potential across multiple medical disciplines, positioning taVNS as a promising new tool in integrative and rehabilitative medicine.

Technical Details and Important Information for taVNS

1. Stimulation Parameters

The effectiveness of taVNS is highly dependent on the specific stimulation parameters used. While standardization remains a challenge in the field, a consensus is emerging around certain ranges.

Frequency refers to the number of electrical pulses delivered per second, measured in Hertz. Most therapeutic protocols utilize low frequency stimulation, typically between 20 Hz and 30 Hz. The 2026 Parkinson's disease trial used a frequency of 25 Hz, while the postoperative headache trial also adopted 25 Hz as its standard. The cardiac surgery delirium trial used 20 Hz.

Pulse width describes the duration of each individual electrical pulse, typically measured in microseconds. Common therapeutic pulse widths range from 200 to 300 microseconds. Many studies use a biphasic waveform, meaning the current alternates direction to prevent net charge buildup and reduce skin irritation.

Intensity is the amplitude or strength of the stimulation, measured in milliamperes. This parameter must be individualized for each patient. The standard practice is to set the intensity at a level that is clearly perceptible as a tingling or pricking sensation but remains below the threshold of pain or discomfort. The specific intensity varies significantly between individuals, often ranging from 10 to 60 mA. The goal is to activate the vagal afferent fibers without causing distress.

Duty cycle refers to the pattern of stimulation on and off. Many protocols use an intermittent pattern, such as 30 seconds of stimulation followed by 30 seconds of rest. This pattern helps prevent neural adaptation and reduces the risk of overstimulation. A session typically lasts 30 minutes.

2. Stimulation Site and Device Placement

The auricular branch of the vagus nerve, also known as Arnold's nerve, supplies sensory innervation to specific regions of the external ear. The most effective stimulation sites are the cymba conchae and the tragus. The cymba conchae is the elevated ridge within the upper hollow of the ear, while the tragus is the small cartilaginous projection just in front of the ear canal.

Most protocols stimulate the left ear rather than the right ear. This preference stems from the observation that right sided vagus nerve stimulation carries a slightly higher theoretical risk of cardiac arrhythmias, as the right vagus nerve has more influence on the sinoatrial node of the heart. However, the overall cardiac risk with taVNS is extremely low, and some studies have successfully used right sided stimulation.

The electrodes are typically adhesive patches or small clips that attach to the skin of the ear. Proper skin preparation, including cleaning the area with an alcohol wipe, is important to ensure good electrical contact and reduce impedance.

3. Treatment Duration and Frequency

The appropriate duration and frequency of taVNS treatment depend on the condition being treated and the specific protocol.

For acute applications, such as postoperative headache or acute ischemic stroke, treatment may be delivered twice daily for a period of 5 to 14 days. The postoperative headache trial administered 30 minute sessions twice daily for 5 days, starting one day before surgery. The acute stroke trial delivered twice daily stimulations for 5 days.

For chronic conditions such as Parkinson's disease, depression, or chronic pain, treatment is typically administered over a longer period. The 2026 Parkinson's disease trial used a 3 week home based protocol. Many chronic pain protocols extend for 4 to 12 weeks, with daily or twice daily sessions.

The total number of sessions matters. The acute stroke trial reported a mean of 8.24 stimulations in the treatment group over the 5 day protocol. Higher cumulative doses may be associated with greater therapeutic effects, though this relationship requires further study.

4. Preconditioning and Foundational Requirements

Before initiating taVNS, several prerequisites should be addressed. A thorough medical evaluation is necessary to rule out contraindications. Patients should be screened for the presence of implanted electronic devices such as pacemakers, defibrillators, or neurostimulators, as the electrical current could theoretically interfere with these devices.

The skin at the intended stimulation site should be examined. Active skin lesions, infections, recent trauma, or surgical scars in the ear area are relative contraindications. A history of ear surgery or known nerve injury in the region may also preclude treatment.

Patients with a history of vagotomy, a surgical procedure that cuts the vagus nerve, will not benefit from taVNS as the target nerve has been severed.

5. Time of Day and Scheduling

For home based protocols, the timing of sessions can be flexible. However, consistency is important for achieving therapeutic effects. Many patients find it helpful to schedule sessions at the same times each day, such as morning and evening, to establish a routine.

Given that taVNS can influence autonomic nervous system activity, some consideration may be given to timing. Stimulation has been shown to increase heart rate variability and promote parasympathetic tone. Evening sessions may support relaxation and sleep quality, while morning sessions may help with alertness and mood regulation for individuals with depression. The 2026 Parkinson's disease trial successfully used a home based protocol, demonstrating the feasibility of flexible scheduling.

6. Diet and Medication Considerations

There are no specific dietary restrictions required for taVNS. Patients should continue taking their prescribed medications unless otherwise directed by their physician. However, it is important to note that taVNS may have additive or synergistic effects with certain medications.

For individuals with inflammatory conditions, taVNS may reduce the need for anti inflammatory drugs over time, though this should be discussed with a healthcare provider. Similarly, for patients with depression or anxiety, taVNS may augment the effects of antidepressant or anxiolytic medications. In the postoperative cardiac surgery trial, patients continued their standard perioperative medication regimens alongside the taVNS intervention.

7. Signs to Be Wary Of and Safety Profile

The safety profile of taVNS is excellent, with no serious adverse events attributed to the therapy in any of the recent large trials.

Common, minor side effects are related to the stimulation itself and the electrode placement. These include a tingling or pricking sensation at the stimulation site, which is expected and indicates that the nerve is being activated. Some individuals experience mild discomfort, skin redness, or minor irritation under the electrodes. These effects are temporary and typically resolve shortly after the stimulation ends or when the electrodes are removed.

More specific side effects have been reported rarely. Changes in heart rate, particularly mild bradycardia, have been observed in some studies. However, the stroke trial reported bradycardia in 11.8 percent of the taVNS group compared to 22.2 percent in the sham group, indicating that the stimulation itself was not responsible. Hypotension occurred in 0 percent of the taVNS group versus 11.1 percent of the sham group in the same trial.

Patients should discontinue stimulation and consult their physician if they experience severe or persistent pain, significant dizziness or lightheadedness, palpitations or irregular heartbeats, shortness of breath, or any neurological symptoms such as new or worsening headache, visual changes, or confusion.

taVNS is contraindicated in individuals with implanted electronic devices, known allergy to electrode materials, or active skin infection at the stimulation site. It should be used with caution in pregnant women, though no specific safety data in pregnancy exists.

Mechanisms of Action: How taVNS Works

The therapeutic effects of taVNS arise from its ability to activate the vagus nerve and, through this activation, modulate a wide range of physiological systems. The mechanism operates at multiple levels, from local nerve activation to global brain network and immune system effects.

At the most basic level, the electrical stimulation depolarizes the afferent fibers of the auricular branch of the vagus nerve. These sensory fibers carry signals from the ear to the brainstem, specifically to the nucleus tractus solitarius, or NTS. The NTS serves as the primary relay station for vagal input and has extensive projections throughout the brain and brainstem.

From the NTS, signals are sent to several key targets. Projections to the locus coeruleus increase the release of norepinephrine, a neurotransmitter involved in arousal, attention, and mood regulation. Projections to the dorsal raphe nucleus increase serotonin release, which plays a critical role in mood, anxiety, and pain perception. Projections to the hypothalamus influence autonomic function, stress responses, and neuroendocrine regulation.

Through these pathways, taVNS can modulate the activity of central brain networks, including the default mode network, which is involved in self referential thought and is often dysregulated in depression. The 2026 Parkinson's disease trial provided direct neuroimaging evidence of these effects, demonstrating that taVNS altered brain activity and connectivity in multiple regions.

Beyond its central nervous system effects, taVNS activates the cholinergic anti inflammatory pathway. This is a vagus nerve dependent mechanism that reduces the production of pro inflammatory cytokines. The vagus nerve communicates with the spleen and other immune organs, leading to the release of acetylcholine, which binds to receptors on immune cells and suppresses inflammation. This mechanism is central to the therapeutic effects of taVNS in inflammatory conditions and was demonstrated in the acute stroke trial, which showed significant reductions in the inflammatory cytokine IL 6 following taVNS treatment.

Detailed Explanations of taVNS Impact

Physiological Impact

The physiological impact of taVNS is broad and systems level. Through its modulation of the autonomic nervous system, taVNS shifts the balance toward parasympathetic dominance. This is reflected in increased heart rate variability, a key marker of cardiovascular health and autonomic resilience. Higher heart rate variability is associated with better stress tolerance, reduced inflammation, and lower risk of cardiovascular events.

The anti inflammatory effects of taVNS are among its most well documented physiological actions. The acute stroke trial demonstrated that taVNS significantly altered the trajectory of interleukin 6, a key pro inflammatory cytokine, in patients with large vessel occlusion stroke. By day 3 after treatment initiation, patients receiving taVNS had significantly lower levels of IL 6, IL 1 beta, and IL 17 alpha compared to sham treated patients. This represents a meaningful modulation of the post stroke inflammatory response, which is known to exacerbate brain injury.

In Parkinson's disease, the 2026 randomized trial documented multiple physiological changes following three weeks of home based taVNS. Serum acetylcholine levels were significantly elevated in the treatment group, and these increases correlated with motor improvement. Acetylcholine is a neurotransmitter that plays a critical role in motor control, and its loss is a hallmark of Parkinson's disease progression. The ability of taVNS to increase circulating acetylcholine levels suggests a disease modifying potential.

Impact on Biomarkers

Recent research has identified several key biomarkers that are modulated by taVNS.

Inflammatory Cytokines are among the most sensitive biomarkers of taVNS effects. The acute stroke trial demonstrated that taVNS significantly changed IL 6 trajectories compared to sham treatment. Post hoc analysis revealed significant differences on day 3 between groups for IL 1 beta, IL 6, and IL 17 alpha. These findings indicate that taVNS exerts a measurable anti inflammatory effect at the systemic level. Ongoing trials are also measuring inflammatory cytokines as secondary outcomes, including the postoperative headache trial and the cardiac surgery delirium trial.

Acetylcholine is a key neurotransmitter and vagal biomarker. The 2026 Parkinson's disease trial found that serum acetylcholine levels were elevated following taVNS and that these elevations correlated with improvements in motor symptoms. This provides a direct mechanistic link between the stimulation and clinical improvement.

Neuroimaging Biomarkers provide objective evidence of brain changes induced by taVNS. The same Parkinson's disease trial used advanced magnetic resonance imaging techniques to document multiple effects. taVNS decreased glutamate levels in the striatum and thalamus, brain regions critically involved in motor control. It increased regional homogeneity values in the rolandic operculum, an area involved in sensory and motor integration. It also enhanced fractional anisotropy in the left hippocampal cingulum and right inferior longitudinal fasciculus, indicating improved white matter integrity in pathways important for memory and emotional regulation.

Heart Rate Variability is a non invasive biomarker of autonomic nervous system function. Multiple studies have documented that taVNS increases heart rate variability, reflecting a shift toward parasympathetic dominance and improved autonomic balance.

Neurological Impact

The neurological effects of taVNS are profound and have been documented across multiple conditions.

In Parkinson's disease, the 2026 randomized trial demonstrated that three weeks of home based taVNS significantly improved motor symptoms, as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III. Non motor symptoms also improved, including quality of life and sleep disturbances. These improvements were accompanied by the neuroimaging changes described above, providing biological validation of the clinical effects.

In acute ischemic stroke, the NUVISTA trial demonstrated that taVNS safely reduced post stroke inflammation. While the trial did not find significant differences in clinical outcomes such as NIHSS or modified Rankin Scale scores at 30 or 90 days, the sample size was relatively small and not powered for clinical efficacy. The significant reduction in IL 6, which was itself correlated with worse neurological outcomes, suggests that taVNS may have disease modifying potential that could be demonstrated in larger trials.

In chronic pain, a systematic review published in 2026 summarized evidence across neuropathic pain, autoimmune disease related pain, gastrointestinal pain, and musculoskeletal pain. The mechanisms identified include activation of central descending pain control pathways, modulation of the cholinergic anti inflammatory pathway, balancing autonomic nervous system function, reshaping functional connectivity in brain networks, regulating neurotransmitter and neuropeptide balance, and inhibiting peripheral and central sensitization processes.

For mood disorders, the narrative review published in 2025 concluded that taVNS may be a safer alternative to invasive vagus nerve stimulation for treatment resistant depression. The mechanisms include increasing norepinephrine secretion, enhancing vagus nerve stimulation adaptability, and improving heart rate variability. Ongoing trials, including the cardiac surgery delirium study, are investigating the effects of taVNS on postoperative anxiety and depression.

Impact on Inflammation and Immune Function

The anti inflammatory effects of taVNS are mediated through the cholinergic anti inflammatory pathway. This pathway was first discovered in animal models of sepsis and has since been validated in human studies. The vagus nerve, when stimulated, releases acetylcholine at its peripheral endings. This acetylcholine binds to alpha 7 nicotinic acetylcholine receptors on macrophages and other immune cells, suppressing the production of pro inflammatory cytokines such as TNF alpha, IL 1 beta, and IL 6.

The acute stroke trial provided the most direct evidence of this mechanism in humans. The significant reduction in IL 6, IL 1 beta, and IL 17 alpha in the taVNS group compared to sham confirms that non invasive vagus nerve stimulation can achieve meaningful anti inflammatory effects. The trial also measured safety endpoints including infections, and there was no difference between groups, indicating that the immune modulation did not compromise host defense.

Stress and Autonomic Regulation Impact

taVNS exerts powerful effects on the stress response and autonomic regulation. The vagus nerve is a primary efferent pathway of the parasympathetic nervous system, and its activation counteracts the sympathetic fight or flight response.

Chronic stress is associated with reduced vagal tone, as measured by low heart rate variability. This state of autonomic imbalance is linked to numerous adverse health outcomes, including cardiovascular disease, depression, anxiety, and chronic inflammation. By directly activating vagal afferents, taVNS can help restore autonomic balance. The observed increases in heart rate variability following taVNS provide direct evidence of this restorative effect.

The 2025 narrative review emphasized that taVNS modulates both the sympathetic and parasympathetic branches of the autonomic nervous system, increasing norepinephrine secretion from the locus coeruleus while also enhancing parasympathetic outflow. This dual effect may explain the broad therapeutic range of taVNS, from the energizing effects needed for depression to the calming effects needed for anxiety.

Possible Conditioning Response and Steps to Optimize Healing

With repeated taVNS sessions, the brain and body may develop a conditioning response. Neuroplastic changes, including the alterations in white matter integrity documented in the Parkinson's disease trial, suggest that the benefits of taVNS may accumulate over time. The increase in fractional anisotropy in the left hippocampal cingulum and right inferior longitudinal fasciculus after only three weeks of treatment is remarkable and indicates that taVNS can induce structural brain changes in a relatively short period.

To optimize healing with taVNS, several steps are recommended.

Adhere to the prescribed protocol consistently. The dose response relationship for taVNS is not fully established, but evidence suggests that more sessions yield greater benefits.

Ensure proper electrode placement and skin preparation. Poor contact can reduce efficacy and increase discomfort.

Work with a healthcare provider to individualize stimulation parameters. The optimal frequency, intensity, and duty cycle may vary by condition and individual.

Combine taVNS with other evidence based therapies. In Parkinson's disease, taVNS is an adjunct to standard medical care, not a replacement. The same applies to depression, chronic pain, and post stroke rehabilitation.

Monitor symptoms and side effects. Keeping a log of symptom severity before and after each session can help track progress and identify optimal timing.

Be patient. While some effects, such as the reduction in inflammatory cytokines, may occur within days, other effects, such as neuroplastic changes, require weeks to months of consistent stimulation.

Conditions That Can Benefit from This Therapy

Based on clinical and scientific evidence, taVNS may benefit a wide range of conditions across multiple medical specialties.

Parkinson's Disease has strong evidence from the 2026 randomized controlled trial, which demonstrated significant improvements in motor symptoms, quality of life, and sleep disturbances after three weeks of home based taVNS. Neuroimaging confirmed changes in brain structure and function, and serum acetylcholine levels increased.

Acute Ischemic Stroke has evidence from the NUVISTA trial, which showed that taVNS safely reduced inflammatory biomarkers including IL 6, IL 1 beta, and IL 17 alpha in patients with large vessel occlusion. While clinical efficacy requires larger trials, the anti inflammatory effect is itself clinically meaningful.

Chronic Pain, including neuropathic pain, autoimmune disease related pain, gastrointestinal pain, and musculoskeletal pain, is supported by a 2026 systematic review. The mechanisms include activation of descending pain control pathways and anti inflammatory effects.

Treatment Resistant Depression and mood disorders are supported by a 2025 narrative review, which concluded that taVNS may be a safer alternative to invasive vagus nerve stimulation. Mechanisms include increased norepinephrine and serotonin release and improved heart rate variability.

Postoperative Delirium and negative emotional states are being investigated in an ongoing 270 patient multicenter randomized trial in cardiac surgery patients. This trial will assess the effects of intraoperative taVNS on delirium, anxiety, and depression.

Postoperative Headache following stent assisted coiling for unruptured aneurysms is being investigated in a 440 patient randomized trial. The trial uses 30 minute sessions twice daily for 5 days, starting one day before surgery.

Tinnitus has mixed evidence, and a systematic review and meta analysis protocol was published in 2024 to clarify whether taVNS is effective and safe for tinnitus. The current evidence remains inconclusive.

Inflammatory Disorders including rheumatoid arthritis and Crohn's disease have been investigated in early studies. The anti inflammatory mechanism of taVNS is well established, and clinical trials are ongoing.

Epilepsy, the original indication for invasive VNS, has been investigated with taVNS, though evidence is less robust than for implanted devices.

Autonomic Dysfunction, including conditions characterized by reduced heart rate variability and autonomic imbalance, may benefit from taVNS through its documented effects on autonomic regulation.

Clinical and Scientific Evidence

The evidence base for taVNS has grown substantially in recent years, with multiple high quality randomized controlled trials published in 2025 and 2026.

The most rigorous trial to date is the 2026 randomized, single blinded, placebo controlled trial of home based taVNS in Parkinson's disease, published in the journal Neurotherapeutics. This trial enrolled patients with Parkinson's disease and randomized them to either active taVNS with specific stimulation parameters or sham stimulation for three weeks. The taVNS group showed significant improvements in motor symptoms measured by MDS UPDRS Part III, as well as improvements in quality of life and sleep disturbances. Neuroimaging revealed decreased glutamate levels in the striatum and thalamus, increased regional homogeneity in the rolandic operculum, and enhanced fractional anisotropy in white matter tracts. Serum acetylcholine levels increased and correlated with motor improvement. No serious adverse events occurred.

The NUVISTA trial, published in Translational Stroke Research in 2026, was a prospective randomized open label blinded endpoint trial of taVNS in acute ischemic stroke. Thirty five patients with large vessel occlusion were randomized to twice daily taVNS or sham for five days. TaVNS treatment significantly changed IL 6 trajectories compared to sham. Post hoc analysis found significant differences on day 3 for IL 1 beta, IL 6, and IL 17 alpha. No significant differences in safety endpoints were found between groups. The trial concluded that taVNS safely reduced post acute ischemic stroke inflammation.

A scoping review published in early 2026 evaluated the therapeutic potential of non invasive vagus nerve stimulation across multiple conditions. The review found promise in treatment resistant depression, anxiety, inflammatory conditions including rheumatoid arthritis and Crohn's disease, migraines, cluster headaches, and post stroke rehabilitation. However, the review noted that variability in study designs and stimulation protocols limits definitive conclusions and called for standardized large scale clinical trials.

A narrative review published in Military Medicine in 2025 systematically reviewed evidence on taVNS for mood disorders and autonomic regulation. The review found that taVNS increases norepinephrine secretion, enhances vagus nerve stimulation adaptability, and improves heart rate variability. The authors concluded that taVNS may be a safer alternative to invasive vagal nerve stimulation for treatment resistant mood disorders, chronic pain, inflammation, cardiovascular dysfunction, inflammatory bowel disease, and Crohn's disease, while calling for further empirical research to elucidate mechanisms and resolve inconsistencies in stimulation parameters.

A systematic review on chronic pain published in Frontiers in Pain Research in 2026 examined clinical efficacy across multiple chronic pain conditions and detailed the neurobiological mechanisms, including activation of central descending pain control pathways, modulation of cholinergic anti inflammatory pathways, balancing autonomic nervous system function, reshaping functional connectivity in brain networks, regulating neurotransmitter and neuropeptide balance, and inhibiting peripheral and central sensitization processes.

A narrative review on safety, parameters, and efficacy published in 2025 included 154 papers and concluded that the safety of taVNS is relatively high. Although minor side effects were reported, no serious adverse events were attributed to taVNS parameters used. The review noted that taVNS could regulate brain activity, motor and mental functions, and autonomic nervous system activity in patients with stroke and Parkinson's disease. However, the review also highlighted the lack of reports on safety and stimulation parameters used, calling for further validation.

Ongoing trials are expected to provide additional high quality evidence. The IMPACT HT trial, a 440 patient randomized trial of taVNS for postoperative headache following aneurysm coiling, is expected to complete primary outcome data collection by July 2027. The cardiac surgery delirium trial, a 270 patient multicenter randomized double blind sham controlled trial of intraoperative taVNS for postoperative delirium and negative emotions, is expected to complete by February 2027.

The tinnitus systematic review and meta analysis protocol, published in BMJ Open in 2024, highlights the need for updated evidence synthesis given conflicting results across existing studies.

A review published in OBM Integrative and Complementary Medicine in 2025 examined the integration of taVNS into integrative medicine, emphasizing its potential across neurology, psychiatry, cardiology, pulmonology, immunology, and gastroenterology. The review called for multicenter studies to unify therapy protocols and consolidate effectiveness evidence.

Conclusion

Transcutaneous auricular vagus nerve stimulation represents a significant advance in the field of non invasive neuromodulation. By delivering low level electrical stimulation to a branch of the vagus nerve accessible in the outer ear, taVNS offers a safe, well tolerated, and practical alternative to surgically implanted vagus nerve stimulation devices. The accumulating evidence from high quality randomized controlled trials, systematic reviews, and ongoing clinical investigations supports its therapeutic potential across a remarkably diverse range of conditions.

The 2026 Parkinson's disease trial demonstrated that home based taVNS improves both motor and non motor symptoms, with neuroimaging confirming structural and functional brain changes and biomarker analysis revealing increased serum acetylcholine. The NUVISTA stroke trial demonstrated that taVNS safely reduces post stroke inflammation, a key driver of secondary brain injury. Systematic reviews support its use in chronic pain, depression, anxiety, and inflammatory disorders. Ongoing trials are investigating its effects on postoperative delirium, postoperative headache, and other conditions.

The mechanisms underlying these broad therapeutic effects are increasingly well understood. taVNS activates the nucleus tractus solitarius in the brainstem, which in turn modulates norepinephrine and serotonin release, influences central brain networks, and activates the cholinergic anti inflammatory pathway. These mechanisms converge to produce effects on motor function, mood, pain perception, inflammation, and autonomic regulation.

Despite the promising evidence, important challenges remain. Variability in stimulation parameters across studies limits the ability to compare results and establish optimal protocols. Larger, longer term trials are needed to confirm efficacy for many indications. The precise dose response relationship, including the optimal frequency, intensity, duration, and cumulative number of sessions, requires further elucidation. Nevertheless, the safety profile of taVNS is excellent, with no serious adverse events attributed to the therapy in any large trial.

For clinicians and patients seeking non pharmacological options for managing chronic conditions, taVNS offers an innovative approach grounded in neuroscience and supported by a growing body of rigorous clinical research. As the field moves toward standardized protocols and larger confirmatory trials, taVNS is poised to become an increasingly important tool in the armamentarium of integrative, rehabilitative, and preventive medicine.